Scientific Reports (Aug 2021)

Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation

  • Gerold Thölking,
  • Brigitte Filensky,
  • Ulrich Jehn,
  • Katharina Schütte-Nütgen,
  • Raphael Koch,
  • Christine Kurschat,
  • Hermann Pavenstädt,
  • Barbara Suwelack,
  • Stefan Reuter,
  • Dirk Kuypers

DOI
https://doi.org/10.1038/s41598-021-95201-5
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Fast metabolism of immediate-release tacrolimus (IR-Tac) is associated with decreased kidney function after renal transplantation (RTx) compared to slow metabolizers. We hypothesized, by analogy, that fast metabolism of extended-release tacrolimus (ER-Tac) is associated with worse renal function. We analyzed data from patients who underwent RTx at three different transplant centers between 2007 and 2016 and received an initial immunosuppressive regimen with ER-Tac, mycophenolate, and a corticosteroid. Three months after RTx, a Tac concentration to dose ratio (C/D ratio) < 1.0 ng/ml · 1/mL defined fast ER-Tac metabolism and ≥ 1.0 ng/ml · 1/mL slow metabolism. Renal function (estimated glomerular filtration rate, eGFR), first acute rejection (AR), conversion from ER-Tac, graft and patient survival were observed up to 60-months. 610 RTx patients were divided into 192 fast and 418 slow ER-Tac metabolizers. Fast metabolizers showed a decreased eGFR at all time points compared to slow metabolizers. The fast metabolizer group included more patients who were switched from ER-Tac (p < 0.001). First AR occurred more frequently (p = 0.008) in fast metabolizers, while graft and patient survival rates did not differ between groups (p = 0.529 and p = 0.366, respectively). Calculation of the ER-Tac C/D ratio early after RTx may facilitate individualization of immunosuppression and help identify patients at risk for an unfavorable outcome.